Amelia Bond, PhD
Are hospitals participating in the federal 340B Drug Pricing Program less motivated to prescribe biosimilars over their higher priced originator products? That’s the conclusion of a recent study published in Health Affairs (2023;42[5]:632-641) that suggests reforms to the drug discount program are needed to nudge hospitals and providers toward using biosimilars.
The research, from a trio of health economists, found that in hospital outpatient settings,